168 related articles for article (PubMed ID: 14633279)
1. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI).
Yount S; Cella D; Banik D; Ashraf T; Shevrin D
Health Qual Life Outcomes; 2003 Nov; 1():69. PubMed ID: 14633279
[TBL] [Abstract][Full Text] [Related]
2. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer.
Cella D; Nichol MB; Eton D; Nelson JB; Mulani P
Value Health; 2009; 12(1):124-9. PubMed ID: 18647260
[TBL] [Abstract][Full Text] [Related]
3. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN).
Cella D; Paul D; Yount S; Winn R; Chang CH; Banik D; Weeks J
Cancer Invest; 2003; 21(4):526-35. PubMed ID: 14533442
[TBL] [Abstract][Full Text] [Related]
4. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer.
Lee WR; McQuellon RP; Harris-Henderson K; Case LD; McCullough DL
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):77-81. PubMed ID: 10656376
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of treatment- and disease-related symptoms in advanced head and neck cancer: validation of the national comprehensive cancer network-functional assessment of cancer therapy-head and neck cancer symptom index-22 (NFHNSI-22).
Pearman TP; Beaumont JL; Paul D; Abernethy AP; Jacobsen PB; Syrjala KL; Von Roenn J; Cella D
J Pain Symptom Manage; 2013 Jul; 46(1):113-20. PubMed ID: 23017622
[TBL] [Abstract][Full Text] [Related]
7. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings.
Giesler RB; Miles BJ; Cowen ME; Kattan MW
Qual Life Res; 2000; 9(6):645-65. PubMed ID: 11236855
[TBL] [Abstract][Full Text] [Related]
8. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.
Yellen SB; Cella DF; Webster K; Blendowski C; Kaplan E
J Pain Symptom Manage; 1997 Feb; 13(2):63-74. PubMed ID: 9095563
[TBL] [Abstract][Full Text] [Related]
9. Development of a symptom index for patients with primary brain tumors.
Lai JS; Jensen SE; Beaumont JL; Abernethy AP; Jacobsen PB; Syrjala K; Raizer JJ; Cella D
Value Health; 2014; 17(1):62-9. PubMed ID: 24438718
[TBL] [Abstract][Full Text] [Related]
10. 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Lehtonen M; Sormunen J; Luukkaala T; Marttila T; McDermott R; Joensuu T; Lehtinen I; Ginman C; Kellokumpu-Lehtinen PL
Acta Oncol; 2022 Aug; 61(8):963-971. PubMed ID: 35847998
[TBL] [Abstract][Full Text] [Related]
11. Validation of the 7-item Functional Assessment of Cancer Therapy-General (FACT-G7) as a short measure of quality of life in patients with advanced cancer.
Mah K; Swami N; Le LW; Chow R; Hannon BL; Rodin G; Zimmermann C
Cancer; 2020 Aug; 126(16):3750-3757. PubMed ID: 32459377
[TBL] [Abstract][Full Text] [Related]
12. Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials.
Robinson DW; Zhao N; Dawkins F; Qi M; Revicki D
Qual Life Res; 2013 Dec; 22(10):2777-86. PubMed ID: 23589119
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.
Esper P; Mo F; Chodak G; Sinner M; Cella D; Pienta KJ
Urology; 1997 Dec; 50(6):920-8. PubMed ID: 9426724
[TBL] [Abstract][Full Text] [Related]
15. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index.
Victorson DE; Beaumont JL; Rosenbloom SK; Shevrin D; Cella D
Psychooncology; 2011 Sep; 20(9):977-83. PubMed ID: 20661866
[TBL] [Abstract][Full Text] [Related]
16. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
Lee WR; McQuellon RP; Case LD; deGuzman AF; McCullough DL
J Urol; 1999 Aug; 162(2):403-6. PubMed ID: 10411047
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
[TBL] [Abstract][Full Text] [Related]
18. Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients.
Degboe A; Ivanescu C; Rohay JM; Turner RR; Cella D
Support Care Cancer; 2019 Nov; 27(11):4189-4198. PubMed ID: 30825026
[TBL] [Abstract][Full Text] [Related]
19. A brief symptom index for advanced lung cancer.
Yount S; Beaumont J; Rosenbloom S; Cella D; Patel J; Hensing T; Jacobsen PB; Syrjala K; Abernethy AP
Clin Lung Cancer; 2012 Jan; 13(1):14-23. PubMed ID: 21729652
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI).
Butt Z; Parikh ND; Beaumont JL; Rosenbloom SK; Syrjala KL; Abernethy AP; Benson AB; Cella D
Cancer; 2012 Dec; 118(23):5997-6004. PubMed ID: 22605658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
